Helen Maddock

Professor

Accepting PhD Students

  • 732 Citations
  • 7 h-Index
20012019
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Helen Maddock has a PhD in Cardiovascular Pharmacology from Cardiff University (Welsh School of Pharmacy). She joined the University of Kent, Bioscience Department as a British Heart Foundation (BHF) funded post-doctoral research fellow, to work under Professors Simon Jarvis and Jeremy Pearson, where she characterised the nucleobase transporters in the heart and human endothelial cells. In 1998 she joined Professor Derek Yellon as a BHF post-doctoral research fellow and Honorary Lecturer, at the Hatter Cardiovascular Institute, part of the Institute of Cardiovascular Sciences, UCL, expanding her PhD studies by investigating intracellular signalling mechanisms associated with myocardial ischaemia-reperfusion injury. During this time she undertook studies using human cardiac tissue obtained from cardiac bypass graft patients.

 

In 2001, she was appointed as a Senior Lecturer in Cardiovascular Pharmacology & Physiology at Coventry University. Professor Maddock currently leads the successful Centre for Sport, Exercise and Life Sciences at Coventry University, in addition to being founder and Chief Scientific Officer of InoCardia Ltd, a Coventry University spin-out company. She has successfully led many research projects, building on experience originally gained in R&D within the pharmaceutical industry (AstraZeneca and GlaxoSmithKline) and academia. Professor Maddock has attracted research and commercial funding from the British Heart Foundation, Heart Research UK, British Pharmacological Society, European Regional Development Fund, Mercia Fund Management, Innovate UK, NC3Rs and the pharmaceutical industry. Her research is driven by the desire to improve cardiac health. Overall, she has made significant contributions to the field of cardiovascular biology, including original peer-reviewed articles, reviews and book chapters. Current research projects include the development of relevant non-clinical heart assays to assess cardiovascular disease related therapies using diseased and “healthy” human heart tissue and cells. In addition to this her team also undertakes clinical and non-clinical research and drug discovery strategies focussed on drug-induced cardiac injury and heart failure.

As Executive Director of the Centre for Sport, Exercise and Life Sciences, Professor Maddock is responsible for carrying out its mission and implementing its business plan. She also supervises basic and translational research, formulates and integrates research activities, and establishes programs that will foster public-private partnerships, philanthropy and commercialization of new drugs, devices and technology.

Research Interests

Cardiac contractile dysfunction ; Mitochondrial activity and energetic ; Drug-induced cardiotoxicity/Safety Pharmacology ; Myocardial stress adaptation and oxidative stress ; Human factor assessment using physiological techniques ; Identifying cardioprotective therapies for treating myocardial ischaemia/reperfusion injury ; Heart Failure

Vision Statement

The objective of my research is the understanding of the disease process and the intracellular signal transduction mechanisms and cellular stress responses that lead to cardiac contractile dysfunction and myocardial injury aligned to diabetes, heart failure and drug induced cardiotoxicity, with an aim to provide a rational basis for prevention or therapeutic intervention, including the involvement of biomarker identification. I have been instrumental in investigating the impact of mitochondrial function aligned to cardiovascular cellular stress responses, as evidenced by my publications. In addition I am currently in the process of exploiting the commercial aspect of my research and I have filed several priority patents to support the university spin-out company - InoCardia.

Fingerprint Dive into the research topics where Helen Maddock is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 2 Similar Profiles
Adenosine A3 Receptors Medicine & Life Sciences
Myocardial Ischemia Medicine & Life Sciences
Wounds and Injuries Medicine & Life Sciences
Assays Chemical Compounds
Mitogens Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Doxorubicin Medicine & Life Sciences
Reperfusion Injury Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2001 2019

1 Downloads (Pure)

Ageing alters the severity of Sunitinib-induced cardiotoxicity: Investigating the mitogen activated kinase kinase 7 pathway association

Cooper, S., Sandhu, H., Hussain, A., Mee, C. & Maddock, H., 1 Jan 2019, In : Toxicology. 411, p. 49-59 11 p.

Research output: Contribution to journalArticle

Open Access
File
Mitogens
Phosphotransferases
Aging of materials
Association reactions
Age Groups

Assessment of Tiron as a cardioprotective agent

Blair, O., 2019

Research output: Thesis (awarded by Coventry University)Doctoral Thesis

1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt
Cardiotonic Agents
Doxorubicin
Caspase 3
Reperfusion

Cardiac stunning during hemodialysis: the therapeutic effect of intra-dialytic exercise

McGuire, S., Horton, E., Renshaw, D., Chan, K., Jimenez, A., Maddock, H., Krishnan, N. & McGregor, G., 2 Oct 2019, (Accepted/In press) In : CKJ: Clinical Kidney Journal. (In-Press), p. (In-Press)

Research output: Contribution to journalReview article

5 Citations (Scopus)
21 Downloads (Pure)

Involvement of mitogen activated kinase kinase 7 intracellular signalling pathway in Sunitinib-induced cardiotoxicity

Sandhu, H., Cooper, S., Hussain, A., Mee, C. & Maddock, H., 1 Feb 2018, In : Toxicology. 394, p. 72-83

Research output: Contribution to journalArticle

Open Access
File
Mitogens
Phosphotransferases
MAP Kinase Kinase Kinase 5
sunitinib
Cardiotoxicity
4 Citations (Scopus)
32 Downloads (Pure)

Attenuation of Sunitinib-induced cardiotoxicity through the A3 adenosine receptor activation

Sandhu, H., Cooper, S., Hussain, A., Mee, C. & Maddock, H., 5 Nov 2017, In : European Journal of Pharmacology. 814, p. 95-105 11 p.

Research output: Contribution to journalArticle

Open Access
File
Adenosine A3 Receptors
HL-60 Cells
MicroRNAs
Protein Kinase C
Neoplasms

Activities 1996 2015

  • 14 Participation in conference

British Cardiovascular Society conference

Helen Maddock (Keynote Speaker)
8 Jun 201510 Jun 2015

Activity: Participating in or organising an eventParticipation in conference

Coventry University, HLS Research Symposium

Helen Maddock (Keynote Speaker)
1 Apr 2015

Activity: Participating in or organising an eventParticipation in conference

Boehringer Ingelheim, Germany Research Symposium

Helen Maddock (Keynote Speaker)
1 Feb 2015

Activity: Participating in or organising an eventParticipation in conference

British Toxicology Society Spring conference

Helen Maddock (Speaker)
3 Mar 2012

Activity: Participating in or organising an eventParticipation in conference

British Toxicology Society Spring conference

Helen Maddock (Speaker)
5 May 2012

Activity: Participating in or organising an eventParticipation in conference